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DOI 10.1016/j.chembiol.2008.11.002Large and lucrative markets could await
the drug that causes significant weight
loss, but developing a medication that is
both safe and effective has stymied the
largest of drug companies. Some new
contenders are nowgrabbing for thebrass
ring by finding creative ways to make you
think you are not hungry.
As researchers unravel the complicated
interplay of brain, behavior, and genetics,
average weight loss of 2.89 kg a year but
also can cause flatulence and greasy,
unpredictable bowel movements. Sibutr-
amine (Meridia) induces an average
weight loss of 4.45 kg yearly via a neuro-
transmitter reuptake inhibitor that en-
hances satiety but can also lead to high
blood pressure, nausea, and insomnia
(Snow et al., 2005). Phentermine, a com-
mon, older, generic, amphetamine-like
Overindulgence is imprinted in our DNA. We are genetically de-
signed to hoard fat to cope with scarcity, but high-calorie food
is now cheap and plentiful, and we exercise less. The CDC esti-
mates that two thirds of American adults are overweight at a
body mass index greater than 25 and 72 million Americans are
obese with a BMI of 30 or more (http://www.cdc.gov/nccdphp/
dnpa/obesity). Worldwide, the WHO estimates 1.6 billion adults
are overweight and 400 million are obese, as developing coun-
tries adopt fast food and sedentary habits.they increasingly regard obesity not as
a lack of willpower, but as a chronic dis-
ease with serious health consequences.
Not only is obesity associated with higher
risk for type 2 diabetes, heart disease, and
certain types of cancer, but excessweight
has anatomical consequences: right-
sided heart failure, hip osteoarthritis, and
cirrhosis of the liver. The psychological
effects are brutal as well.
Losing just 5%–10% of your body
weight can reduce the risk of diabetes
and heart disease; such a small amount,
but for many, so hard to do. A third of
the people who lose weight in lifestyle
modification programs gain it back in a
year. Most gain back what they lost within
five years, but this varies by ethnic group
and exercise levels (Weiss et al., 2007).
A Few Big Buts
Annoying side effects and only modest
effectiveness have meant a lukewarm
reception for FDA-approved weight loss
drugs such as xenical (Orlistat), which
blocks fat absorption and causes anappetite suppressant approved for short-
term use, causes an average loss of 3.6 kg
over 6 months.
Merck just halted development of its
cannabinoid-1 (CB1) receptor antagonist
Taranabant, an appetite suppressant, as
the effective dose caused anxiety, irrita-
bility, and depression. Neurological and
psychiatric side effects prevented Sanofi
Aventis’ CB1 inhibitor rimonabant (Acom-
plia) entry into the European and U.S.
markets. And Pfizer halted development
of its weight loss compound.
According to Dr. Caroline Apovian,
director of clinical research for the Obe-
sity Research Center at Boston Medical
Center, the FDA requires companies that
deal with receptors that affect mood to
do 5 year safety studies. Drug companies
report that the investment required will
not be offset by sales because the drugs
are not currently covered under health
insurance. (Apovian discloses she is on
the advisory boards of Merck, Sanofi
Aventis, and Arena Pharmaceuticals and
has received study funding from com-Chemistry & Biology 15, November 24, 2008panies including Orexigen, Pfizer, and
Amylin.)
Apovian prescribes weight loss drugs
both for their approved indications and
off-label as adjuncts to encourage pa-
tients with a bit of success to get them
motivated to change behavior. ‘‘The best
give 10% weight loss,’’ Apovian said.
‘‘Youarenot going toget the100pounds.’’
All appetite suppressants have a re-
bound effect. Go off them without chang-
ing behavior and the pounds come back.
‘‘If you really considered obesity to be
a disease, then why would you stop the
drug,’’ Apovian asked. People who don’t
have a problem paying for diabetes or
blood pressure drugs won’t stay on their
obesity drugs, according to Apovian, not
because of side effects, but because
they are expensive, and are not covered
by health insurance. ‘‘Meridia is over
$100 a month,’’ Apovian said. ‘‘People
cannot afford this month after month, to
keep their 10%weight loss.’’ On the other
hand, according to Apovian, surgery to in-
stall a gastric band can provide a 17%–
20% weight loss, and while some people
would consider that an easy way out,
making a lifestyle shift is hard.
New Contenders
San Diego-based Arena Pharmaceuti-
cals’ (http://www.arenapharm.com) oral
antiobesity drug Lorcaserin (lorcaserin
hydrochloride) is now in stage 3 trials.
Arena’s drug candidates selectively tar-
get G protein-coupled receptors (GPCRs)
with and without known natural ligands
(GPCRs without natural ligands are com-
monly referred to as ‘‘orphan’’). GPCRs
are proteins that are located in the cell
membrane and mediate cell signaling.
The challenge is to be selective while
effective. As weight regulation is con-
trolled by multiple pathways in the brain,
triggering the wrong receptor can cause
psychiatric problems or heart damage.
Lorcaserin targets the 5-HT2C serotonin
receptor in the hypothalamus, an area of
the brain that mediates satiety andª2008 Elsevier Ltd All rights reserved 1139
Chemistry & Biology
Innovationsmetabolism. However, this receptor is
similar to two others in its subclass,
HT2A, linked to hallucinations and HT2B,
associated with heart damage.
Obesity drug development is still shad-
owed by the debacle of Fen-phen, phen-
termine combined with fenfluramine or
dexfenfluramine. Phentermine and fen-
fluramine were approved in the 1970s as
individual agents for short-term use, but
people used them off-label long term. In
1997, the FDA called for fenfluramine and
its enantiomer dexfenfluramine to be
taken off the market when Mayo Clinic
researchers found heart valve damage
and pulmonary hypertension in patients.
Manufacturer American Home Products,
now Wyeth, paid out over $21 billion in
lawsuits.
According to Dominic Behan, PhD,
chief scientific officer and Arena co-
founder, fenfluramine was the most effec-
tive weight loss agent ever, especially in
combination with phentermine. Patients
lost ten percent of their body weight and
more. ‘‘The problem was nonselectivity,’’
Behan said. ‘‘Our goal, back in 2001,
was to come up with a compound that
was a selective HT2C agonist.’’
In Arena’s phase 2b 12 week studies of
various doses, Lorcaserin at the highest
dose of 20 mg caused a 3.6 kg placebo-
adjusted weight loss without diet or exer-
cise. A third of people had weight loss of
5 percent or higher. Some study subjects
reported transient headache and nausea,
but Lorcaserin passed a 12 month inde-
pendent echocardiographic check for
heart valve damage.
Lorcaserin is now in BLOOM, a double-
blind, randomized, and placebo-con-
trolled 2 year trial of 3,100+ overweight
and obese patients, as well as two other
1 year phase 3 trials, BLOSSOM and
BLOOM-DM for diabetes, of 3,750 over-
weight and obese patients. According to
Behan, the weight loss caused by most
drugs plateaus at 6 months or a year,
but Lorcaserin offers progressive weight
loss over time.
Spoiling the Treat
To La Jolla, CA, based Orexigen Thera-
peutics (http://www.orexigen.com), a
cupcake may as well be crack cocaine.
Their strategy is to ruin the pleasure of
eating it. ‘‘In order to affect mechanisms
that are very tightly regulated like energy
balance, oftentimes a single approach1140 Chemistry & Biology 15, November 24,may not be sufficient,’’ said Dr. Eduardo
Dunayevich, Orexigen chief medical offi-
cer. Compensatory mechanisms kick in.
‘‘A great deal of vigilance andmodification
of lifestyle is necessary,’’ Dunayevich
said. ‘‘Unfortunately it is difficult for people
tomaintain changes in life. Think about the
New Year’s resolutions that people make.
In obesity it is compounded as there is
increasing evidence that certain types of
food that are very calorically rich in fat
and sugar are also perceived as very
rewarding.’’
Orexigen’s lead compound Contrave
combines sustained-release buproprion,
a generic antidepressant also used to kick
the cigarette habit, and sustained-release
generic naltrexone, used in its immediate
form to treat opioid addiction and alcohol-
ism, to block the reward centers of the
brain as well as receptors in the hypothal-
amus that regulate energy balance and
metabolism.
In phase 2b trials comparing dosages,
Contrave showed between 8% and 10%
weight loss over 48 weeks in the 88
healthy obese people who finished the
trials on Contrave, out of 171 who were
started on it. Side effects included head-
aches, dizziness, nausea, and insomnia.
Contrave is now in four separate 56 week,
Phase 3 clinical trials of several thousand
patients. Orexigen says that Contrave can
cause progressive, sustained weight loss
as well as potentially stave off symptoms
of depression. Orexigen’s phase 2 com-
pound, Empatic, combines buproprion
and zonasimide, an anticonvulsant.
Diet docs are watching another San
Diego company, Amylin (http://www.
amylin.com) (Wolfson, 2007), which is
testing an injectable combination of pram-
lintide, a synthetic analog of amylin, a neu-
rohormone secreted by the pancreas that
regulates appetite and blood glucose, and
metreleptin (methionyl recombinant lep-
tin), a neurohormone secreted by fat cells
involved in regulating metabolism and
body weight. Phase 2 studies showed a
weight loss of 12.7% over 24 weeks.
One hundred and seventy-seven patients,
averaging 205 lbs at the study start, were
treated with the combo and lost an aver-
age of 25 lbs, compared with an average
of 17 lbs with pramlintide alone. Side ef-
fects included transient headache and
nausea.
Tesofensine, developed by Danish
company NeuroSearch (http://www.2008 ª2008 Elsevier Ltd All rights reservedneurosearch.com), achieved the best
scores yet, twice theweight loss of current
approved drugs, but it is still early in devel-
opment. A member of the phenyltropane
family and originally investigated to treat
Alzheimer’s and Parkinson’s disease,
tesofensine functions as amixed reuptake
inhibitor of certain neurotransmitters. It
boosts dopamine in the reward center of
the forebrain, and noradrenaline and sero-
tonin in the hypothalamus, to raisemetab-
olism and suppress appetite. In TIPO-1,
a randomized, placebo-controlled phase
2 study of 203 obese patients (161 pa-
tients completed the study) on an en-
ergy-restricted diet, the 0.5 mg dose of
tesofensine provided a placebo-adjusted
weight loss of 11.3 kg in 24 weeks. Side
effects included elevated blood pressure
at higher doses, dry mouth, nausea,
constipation, and insomnia.
I’ll Have What She Is Having
It remains ambiguous as towhether short-
term chemical intervention for weight loss
can enable great numbers of people to
change their ways, or if many will have
to take drugs indefinitely. Some intriguing
people are providing clues. It is just too
bad nobody knows how to bottle what
they’ve got. Graham Thomas, MS, a re-
searcher at Brown University’s Medical
School, tracks a group of 6000 people
who lost 30 lbs or much more and kept it
off more than a year in the NationalWeight
Control Registry (http://www.nwcr.ws/
default.htm). What makes them different?
They perpetually stay in bootcamp: they
eat breakfast, follow a low-fat, low-calorie
diet, and exercise a lot. ‘‘The most suc-
cessful of these registry participants are
working very hard to use basic skills, such
as self monitoring, and keeping high levels
of physical activity,’’ said Thomas. ‘‘They
are expending a lot of effort early on. It be-
comes easier after a couple of years when
it becomes part of the fabric of their lives.’’
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